About The Study: In this randomized clinical trial, among East Asian adults with overweight or obesity, with or without type 2 diabetes, oral semaglutide, 50 mg, led to a superior and clinically meaningful reduction in body weight compared with placebo, with a safety profile consistent with the glucagon-like peptide-1 receptor agonist class.
Corresponding Authors: To contact the corresponding authors, email Takashi Kadowaki, MD, PhD, (t-kadowaki@toranomon.kkr.or.jp) and Kyoung-Kon Kim, MD, PhD, (zaduplum@gilhospital.com).
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamainternmed.2025.3599)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2025.3599?guestAccessKey=99e30b83-caf2-456c-a6d6-e5a95aa2c22a&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=080425
Journal
JAMA Internal Medicine